BAMIPINE LACTATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H24N2.C3H6O3
Molecular Weight	370.4852
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.CN1CCC(CC1)N(CC2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=VUNFQOFEWHEROV-UHFFFAOYSA-N

InChI=1S/C19H24N2.C3H6O3/c1-20-14-12-19(13-15-20)21(18-10-6-3-7-11-18)16-17-8-4-2-5-9-17;1-2(4)3(5)6/h2-11,19H,12-16H2,1H3;2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Molecular Formula	C19H24N2
Molecular Weight	280.4073
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.drugs.com/international/bamipine.html | http://en.pharmacodia.com/web/drug/1_12084.html

Bamipine (trade name Soventol) is a sedating antihistamine with pronounced sedative effects. Bamipine is a pharmaceutical drug acting as an H1 antihistamine with anticholinergic properties. It is used as an antipruritic ointment. Bamipine hydrochloride has been given by mouth. Bamipine, bamipine lactate, and bamipine salicylate have all been applied topically.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 316 Target ID: CHEMBL3943 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D07197 \| https://www.ncbi.nlm.nih.gov/pubmed/18977145	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Allergy 44 Sources: http://www.ndrugs.com/?s=bamipine http://www.druginfosys.com/drug.aspx?drugcode=1567&type=1	Primary		Approved 8583	Soventol Approved Use Allergic conditions

Doses

Dose	Population	Adverse events
100 mg 4 times / day multiple, oral Recommended Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: https://www.medindia.net/doctors/drug_information/bamipine.htm	unhealthy, CHILD\|ADOLESCENT\|ADULT Health Status: unhealthy Age Group: CHILD\|ADOLESCENT\|ADULT Food Status: UNKNOWN Sources: https://www.medindia.net/doctors/drug_information/bamipine.htm	Other AEs: Drowsiness, Drowsiness... Other AEs: Drowsiness Drowsiness Sources: https://www.medindia.net/doctors/drug_information/bamipine.htm

AEs

AE	Significance	Dose	Population
Drowsiness		100 mg 4 times / day multiple, oral Recommended Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: https://www.medindia.net/doctors/drug_information/bamipine.htm	unhealthy, CHILD\|ADOLESCENT\|ADULT Health Status: unhealthy Age Group: CHILD\|ADOLESCENT\|ADULT Food Status: UNKNOWN Sources: https://www.medindia.net/doctors/drug_information/bamipine.htm
Drowsiness		100 mg 4 times / day multiple, oral Recommended Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: https://www.medindia.net/doctors/drug_information/bamipine.htm	unhealthy, CHILD\|ADOLESCENT\|ADULT Health Status: unhealthy Age Group: CHILD\|ADOLESCENT\|ADULT Food Status: UNKNOWN Sources: https://www.medindia.net/doctors/drug_information/bamipine.htm

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 CYP1A2 2153 CYP2C19 2057

Drug as perpetrator

Target	Modality	Activity
P-gp 1932	inhibitor 4027 Sources: https://link.springer.com/chapter/10.1007/978-3-319-09801-2_7	moderate
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/72075#section=Biological-Test-Results Page: 58.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/72075#section=Biological-Test-Results Page: 59.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/72075#section=Biological-Test-Results Page: 52.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/72075#section=Biological-Test-Results Page: 54.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/72075#section=Biological-Test-Results Page: 1.0	yes [IC50 0.1096 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/72075#section=Biological-Test-Results Page: 3.0

PubMed

Title	Date	PubMed
Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives.	2008 Dec 15	18977145

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 50-100 mg 3-4 times/day.

Route of Administration: Oral

In Vitro Use Guide

Bamipine treatment resulted in 29% of inhibition of Mycobacterium tuberculosis H37Rv (after 4 days by microplate alamar blue assay) at 6.25 ug/mL.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:48:51 GMT 2025` Edited by `admin` on `Mon Mar 31 18:48:51 GMT 2025`
Record UNII	6K8KNJ07D8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BAMIPINE LACTATE

Common Name

English

MULTIFUNGIN COMPONENT BAMIPINE LACTATE

Preferred Name

English

Bamipine lactate [WHO-DD]

Common Name

English

4-PIPERIDINAMINE, 1-METHYL-N-PHENYL-N-(PHENYLMETHYL)-, MONO(2-HYDROXYPROPANOATE)

Common Name

English

PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH 1-METHYL-N-PHENYL-N-(PHENYLMETHYL)-4-PIPERIDINAMINE (1:1)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578